We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-1.23%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$34M
Cap. Flow
+$67.9M
Cap. Flow %
20.98%
Top 10 Hldgs %
90.01%
Holding
19
New
2
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
VERA icon
Vera Therapeutics
VERA
+$46M
2
OKUR
OnKure Therapeutics
OKUR
+$21.9M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 93.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.81B
$93.6M 28.94%
4,168,718
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$708M
$40.7M 12.59%
1,203,135
– –
VERA icon
3
Vera Therapeutics
VERA
$2.3B
$38.5M 11.91%
+2,960,231
New +$46M
SIEN
4
DELISTED
Sientra, Inc.
SIEN
$19M 5.88%
239,084
– –
OKUR
5
OnKure Therapeutics
OKUR
$154M
$18.2M 5.62%
+196,222
New +$21.9M
SRRA
6
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$16.8M 5.2%
871,125
– –
ACET icon
7
Adicet Bio
ACET
$85.2M
$16.6M 5.12%
100,962
– –
VRNA
8
DELISTED
Verona Pharma
VRNA
$16M 4.95%
2,457,499
– –
SLNO
9
DELISTED
Soleno Therapeutics
SLNO
$11.6M 3.6%
686,840
– –
XCUR icon
10
Exicure
XCUR
$10.2M
$10.4M 3.21%
46,513
– –
NCNA
11
NuCana
NCNA
$5.49M
$9.2M 2.84%
667
– –
PRTK
12
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$7.09M 2.19%
1,041,131
– –
SYRE icon
13
Spyre Therapeutics
SYRE
$8.54B
$1.67M 0.52%
9,620
– –
MTEM
14
DELISTED
Molecular Templates, Inc.
MTEM
$1.56M 0.48%
13,333
– –
XFOR icon
15
X4 Pharmaceuticals
XFOR
$375M
$1.49M 0.46%
7,663
– –
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
$571K 0.18%
131,036
– –
OBSV
17
DELISTED
ObsEva SA Ordinary Shares
OBSV
$266K 0.08%
87,999
– –
OCGN icon
18
Ocugen
OCGN
$416M
$57K 0.02%
7,111
– –

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q2 2021 Portfolio in Review

As of Q2 2021, Abingworth held 19 positions worth $324M, up 12% from $290M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Abingworth deployed $67.9M of net new capital in Q2 2021, opening 2 new positions. Its largest new stake was Vera Therapeutics: 2,960,231 shares worth $38.5M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 90% a quarter earlier.

  • Abingworth's largest Q2 2021 buy was Vera Therapeutics: 2,960,231 shares worth $38.5M.
  • Abingworth's ten largest holdings make up 90% of its $324M portfolio in Q2 2021.
  • Abingworth opened 2 new positions and closed 0 in Q2 2021.
  • Abingworth's portfolio value rose 12% quarter-over-quarter to $324M.

Based on Abingworth's 13F filing for Q2 2021, filed 16 Aug 2021.